智通财经APP获悉，昭衍新药(06127)涨超4%，截至发稿，涨4.34%，报21.66港元，成交额2.09亿港元。
消息面上，昭衍新药发布公告，2025年前三季度该集团取得营业收入9.85亿元，同比减少26.23%；归母净利润8070.61万元，去年同期亏损7030.71万元。公告指出，受多种因素综合影响，公司前三季度累计新签订单金额约人民币16.4亿元，截止本报告期末，公司整体在手订单金额约人民币25亿元。
智通财经APP获悉，昭衍新药(06127)涨超4%，截至发稿，涨4.34%，报21.66港元，成交额2.09亿港元。
消息面上，昭衍新药发布公告，2025年前三季度该集团取得营业收入9.85亿元，同比减少26.23%；归母净利润8070.61万元，去年同期亏损7030.71万元。公告指出，受多种因素综合影响，公司前三季度累计新签订单金额约人民币16.4亿元，截止本报告期末，公司整体在手订单金额约人民币25亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.